DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2016/0244741 A1 Russell Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2016/0244741 A1 Russell Et Al US 20160244741A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0244741 A1 Russell et al. (43) Pub. Date: Aug. 25, 2016 (54) POLYMERENGINEERED REGENERATING Publication Classification BOSCAVENGERS (51) Int. Cl. (71) Applicant: CARNEGE MELLON CI2N 9/96 (2006.01) UNIVERSITY, Pittsburg, PA (US) A638/48 (2006.01) A647/48 (2006.01) (72) Inventors: Alan J. Russell, Gibsonia, PA (US); Hironobu Murata, Pittsburgh, PA (US); CI2N 9/76 (2006.01) Chad Cummings, Pittsburgh, PA (US); CI2N 9/16 (2006.01) Richard R. Koepsel, Pittsburgh, PA A638/46 (2006.01) (52) U.S. Cl. (US) CPC. CI2N 9/96 (2013.01); C12N 9/16 (2013.01); (21) Appl. No.: 15/026,093 A61K 38/465 (2013.01); A61K47/48 176 (2013.01): CI2N 9/6427 (2013.01); A61 K (22) PCT Fled: Oct. 3, 2014 38/4826 (2013.01); C12Y-301/01 007 (2013.01); CI2Y 304/21001 (2013.01) (86) PCT NO.: PCT/US1.4/59171 S371 (c)(1), (57) ABSTRACT (2) Date: Mar. 30, 2016 Related U.S. Application Data Embodiments of the invention provide at least one polymer (60) Provisional application No. 61/961,097, filed on Oct. covalently conjugated to an esterase. The at least one polymer 3, 2013. includes a plurality of Oxime functional groups. Patent Application Publication Aug. 25, 2016 Sheet 1 of 19 US 2016/0244741 A1 E + 1 c > E + R — E + IR F.G. 1 Patent Application Publication Aug. 25, 2016 Sheet 2 of 19 US 2016/0244741 A1 R ar R Y a R w R R R 1- - n E0X - - + is R R - ? R R w . R Y R FG. 2 Patent Application Publication Aug. 25, 2016 Sheet 3 of 19 US 2016/0244741 A1 x stor $8 &888x Syss): 60 °C, 3 h SSX$88-88-8s x 8. FG. 3A Patent Application Publication Aug. 25, 2016 Sheet 4 of 19 US 2016/0244741 A1 i Nyir specisirs of sortine containing polyer I 3&iša-Šs a $2. assies by is 8:88: xy--------------xx-x-xy-y-ex-x-xx-xx-xx-x-x sists & & S.S. S.S. & 8 S& 8. 8, FG. 3B $x,Yess s^x,** iss & &-Saxxxxx. x^. s S. & 2-pyridine aidioxine oiuene, i20'c FG. 3C Patent Application Publication Aug. 25, 2016 Sheet 6 of 19 US 2016/0244741 A1 ED-NHS, wate: W FIG. 3E Patent Application Publication Aug. 25, 2016 Sheet 7 of 19 US 2016/0244741 A1 AChE, Buffer, SSYs S.S &S SS Patent Application Publication Aug. 25, 2016 Sheet 8 of 19 US 2016/0244741 A1 y & x --...--S 3. N Y. Y. - AChEee with ARR initiator bound to annine groups Šs Sulfonate monomer AR + Cu(1)Br, liganda-la. *S^ y o \ Š AS. so- K a toy-stiforate-AChE conjugate FG. 4A Patent Application Publication Aug. 25, 2016 Sheet 9 of 19 US 2016/0244741 A1 S .S X - s s w sessmewsweexsexyrgrks sys8* past fi 4.0 3.0 . O FG. 4B Patent Application Publication Aug. 25, 2016 Sheet 10 of 19 US 2016/0244741 A1 roy(2°AN-ACE & & xistiys six & 88 Š $8 is& is:s F.G. 5 Patent Application Publication Aug. 25, 2016 Sheet 11 of 19 US 2016/0244741 A1 Šs, s NH \- ti. - c. O*- - Y. Ö Y ACE-initiator y Airie N {{{titigate yer Cu()ci-Mes SREY water, C, 4 a AChE-PDMAAIAzide conjugate F.G. 6A Patent Application Publication Aug. 25, 2016 Sheet 12 of 19 US 2016/0244741 A1 N.R of AChE-Fi:AAiAxide corjigate www.www.rxexpyxswoxyxx-xxyyxx. Rys& 38 s& &. & & F.G. SB Patent Application Publication Aug. 25, 2016 Sheet 13 of 19 US 2016/0244741 A1 AChE-PDMAAJAzide conjugate & Alkyne-2-PAM Br CuSO4, HMTETA N - Ascoric acid N ^-a { W {{ 3 () is l i. s8 YssYSYS& RS '^s.Ns s Š s - s AChE-PAA:2-PA conjugate f --&ssr s SS- 88s F.G. 6C Patent Application Publication Aug. 25, 2016 Sheet 14 of 19 US 2016/0244741 A1 Nir of AChE-PSAAF2-PA conjugate i. :- aim k s ------------a^^^s. \\-yasa. F.G. 6) Patent Application Publication Aug. 25, 2016 Sheet 15 of 19 US 2016/0244741 A1 H NER of Aikyne-2-PAR d sta^\sssssssssssssssssssssssssssaara-ašai ill ^ --- ole & E && 8 visaw FIG. 6E Patent Application Publication Aug. 25, 2016 Sheet 16 of 19 US 2016/0244741 A1 Patent Application Publication Aug. 25, 2016 Sheet 17 of 19 US 2016/0244741 A1 i A. +W, y S. c\-e/ - e i ? \ . g f y i &s co-o & *ix. & r * , 8 c sk as f y s . Patent Application Publication Aug. 25, 2016 Sheet 18 of 19 US 2016/0244741 A1 is ; it is Patent Application Publication Aug. 25, 2016 Sheet 19 of 19 US 2016/0244741 A1 100 S 80 is 60 5 40 Š S} SS Š & & Š 20 Š S - POA CHT Š Native CHT 0 -------------------------------------------------------------------------------------------------------------- : O 5 O 15 2O 25 30 35 US 2016/0244741 A1 Aug. 25, 2016 POLYMERENGINEERED REGENERATING ketoxime. In various aspects, the invention may include a BOSCAVENGERS composition as provided in any of the aspects of the compo sition described herein, wherein the plurality of oxime func FIELD OF THE INVENTION tional groups may comprise at least one bis-pyridinium 0001. This invention describes the development of a broad Oxime. spectrum biocatalytic scavenger for use as an organophos 0008. In various aspects, the invention may include a com phate (OP) detoxifying agent. position as provided in any of the aspects of the composition described herein, wherein the at least one polymer covalently conjugated to the esterase may comprise a long lived covalent BACKGROUND OF THE INVENTION conjugate. 0002 The dramatic tragedy in the reemergence of chemi 0009. In various aspects, the invention may include a com cal weapons use in Syria highlights like never before the position as provided in any of the aspects of the composition urgent need to provide effective medical countermeasures for described herein, wherein the long lived covalent conjugate nerve agent poisoning. Less talked of, but even more urgent, may comprise a conjugate that is maintained in the body for a is the need for countermeasures against organophosphate time period ranging from at least one 24 hour day and pref (OP) pesticide poisoning that kills hundreds of thousands erably for more than about one day to more than about one world-wide every year. Although most OP pesticides were week. The long lived covalent conjugate may be maintained banned for use in the US, they still exist and are produced in in the body for a period of time of at least one week, or at least Kilo-tons in other countries and are easily accessible. Some two weeks, and preferably for a period of time sufficient to of them are highly toxic as witnessed by the fatal poisoning of eliminate or significantly reduce the inhibiting function of the school children in India in July 2013 caused by monocroto OP toxin. phos contamination of cooking oil. OP pesticides are a major 0010. In various aspects, of the invention, any of the worldwide health problem, even without accidental or delib aspects of the composition described herein may comprise at erate release with OP self-poisoning (suicide), responsible least one polymer which may have at least one environmen for 200,000 deaths a year worldwide. Eddleston M, Buckley tally responsive monomer. NA, Eyer P. Dawson A H. Management of acute organophos 0011. In various aspects of the invention, any of the phorus pesticide poisoning. Lancet, 371: 597-607 (2008). aspects of the composition described herein may comprise, at Further these poisonings are difficult to treat with the current least one polymer having a polymer length of two repeat standards of therapy. units, and preferably greater than two repeat units, and more preferably a polymer length ranging from a minimum of at SUMMARY OF THE INVENTION least 2 monomer repeats to about 1000 monomer repeats. In 0003. The present investigation represents a solution for certain aspects of the composition, there may be greater than the need for countermeasures against organophosphate pes 1000 monomer repeats. The only upper limit on the number ticide poisoning. A broad spectrum regenerating scavenger or length of monomers is that number or length that will avoid for use as an OP compound detoxifying agent following acute hindering contact of the oXime functional group or groups exposure is described herein. sufficient to interact with the active site of the enzyme for 0004. Accordingly, the present disclosure may include neutralization of the inhibiting moiety. various aspects of a composition and methods for making and 0012. In various aspects, the invention may include a com using the composition. For example, in various aspects, the position as provided in any of the aspects of the composition invention described herein provides a composition compris described herein, wherein the at least one polymer may be a ing at least one polymer covalently conjugated to an esterase. co-polymer that may comprise at least two different mono The at least one polymer may comprise a plurality of oxime mers, wherein at least one monomer may comprise a member functional groups. selected from the group consisting of aldoximes, ketoximes, 0005. In various aspects, the invention may include a com muco-adhesion monomers, polyethylene glycol, bis-pyri position wherein the esterase may comprise a member dinium oximes, N,N-dimethylacrylamide, N-isopropylacry selected from the group consisting of acetylcholinesterase lamide, (meth)acrylate, N,N-dimethylaminoethyl methacry and butyrylcholinesterase. In various aspects, the invention late, carboxyl acrylamide, 2-hydroxylethylmethacrylate, may include a composition wherein the esterase may not N-(2-hydroxypropyl)methacrylamide, quaternary ammo comprise acetylcholinesterase.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Time Dependent Dual Effect of Anti-Inflammatory Treatments On
    Neurotoxicology 74 (2019) 19–27 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Full Length Article Time dependent dual effect of anti-inflammatory treatments on sarin- induced brain inflammation: Suggested role of prostaglandins T ⁎ Shira Chapman, Ettie Grauer , Rellie Gez, Inbal Egoz, Shlomi Lazar Israel Institute for Biological Research, Israel ARTICLE INFO ABSTRACT Keywords: A common consequence of exposure to organophosphate nerve agents is the centrally mediated seizure activity Sarin that appears even after conventional treatment with atropine and oximes. We have previously demonstrated a Organophosphates major inflammatory response with subsequent brain damage which was correlated with the duration of the fl Anti-in ammatory sarin-induced seizures (Chapman et al., 2006). In the present work seizures were induced by the nerve agent Prostaglandins sarin (1.2 LD50) insufficiently treated 1 min later by atropine and trimedoxime bromide (TA), with additional Convulsions midazolam treatment either 5 or 30 min after continuous seizure activity. The efficacy of both steroidal and nonsteroidal anti-inflammatory drugs (NSAIDs), as well as other drugs that were reported as beneficial in neuroprotection, were evaluated for their contribution as adjunct treatment against sarin induced seizures and the ensuing inflammatory brain damage. Results show that both steroids and NSAIDs were harmful when ad- ministered during convulsions, and steroids were at best ineffective if administered at their termination. However, if administered at termination of convulsions, the NSAID ibuprofen, the selective COX 2 inhibitor nimesulide and the PLA2 inhibitor quinacrine were partially effective in reducing brain inflammatory markers. Administration of exogenous analogs of prostaglandins (PGE2) immediately following sarin-induced convulsions was found to have a beneficial effect in reducing brain inflammatory markers measured at 24 h and one week post sarin exposure.
    [Show full text]
  • The Nutrition and Food Web Archive Medical Terminology Book
    The Nutrition and Food Web Archive Medical Terminology Book www.nafwa.
    [Show full text]
  • Download S/2013/735
    United Nations A/68/663–S/2013/735 General Assembly Distr.: General 13 December 2013 Security Council Original: English General Assembly Security Council Sixty-eighth session Sixty-eighth year Agenda item 33 Prevention of armed conflict Identical letters dated 13 December 2013 from the Secretary-General addressed to the President of the General Assembly and the President of the Security Council I have the honour to convey herewith the final report of the United Nations Mission to Investigate Allegations of the Use of Chemical Weapons in the Syrian Arab Republic (see annex). I would be grateful if the present final report, the letter of transmittal and its appendices could be brought to the attention of the Members of the General Assembly and of the Security Council. (Signed) BAN Ki-moon 13-61784 (E) 131213 *1361784* A/68/663 S/2013/735 Annex Letter of transmittal Having completed our investigation into the allegations of the use of chemical weapons in the Syrian Arab Republic reported to you by Member States, and further to the report of the United Nations Mission to Investigate Allegations of the Use of Chemical Weapons in the Syrian Arab Republic (hereinafter, the “United Nations Mission”) on allegations of the use of the chemical weapons in the Ghouta area of Damascus on 21 August 2013 (A/67/997-S/2013/553), we have the honour to submit the final report of the United Nations Mission. To date, 16 allegations of separate incidents involving the use of chemical weapons have been reported to the Secretary-General by Member States, including, primarily, the Governments of France, Qatar, the Syrian Arab Republic, the United Kingdom of Great Britain and Northern Ireland and the United States of America.
    [Show full text]
  • Professor Jo Klaveness School of Pharmacy University of Oslo
    SUPERVISORS Professor Jo Klaveness School of Pharmacy University of Oslo Associate professor Pål Rongved School of Pharmacy University of Oslo 1 TABLE OF CONTENTS TABLE OF CONTENTS 1 ABBREVIATIONS..........................................................................5 2 ABSTRACT.....................................................................................6 3 INTRODUCTION............................................................................7 3.1 Acetylcholine- a neurotransmitter Synthesis, release and inactivation ... 7 3.1.1 Structure of acetylcholinesterase .................................................................... 8 3.2 Anticholinesterases interfere with acetylcholine activity ........................ 9 3.3 Effects of anticholinesterases................................................................... 9 3.4 Different groups of anticholinesterases.................................................. 10 3.4.1 Short- acting anticholinesterases .................................................................. 10 3.4.2 Medium- duration anticholinesterases .......................................................... 11 3.4.3 Irreversible anticholinesterases..................................................................... 12 3.5 Nerve agents: Irreversible anticholinesterases....................................... 13 3.5.1 The dawn of a deadly weapon ...................................................................... 14 3.5.2 Biochemistry................................................................................................
    [Show full text]
  • General Prescription
    GENERAL PRESCRIPTION LESSON 1. INTRODUCTION. PRESCRIPTION. SOLID MEDICINAL FORMS Objective: To study the structure of the prescription, learn the rules and get practical skills in writing out solid medicinal forms in prescription. To carry out practical tasks on prescriptions it is recommended to use Appendix 1. Key questions: 1. Pharmacology as a science and the basis of therapy. Main development milestones of modern pharmacology. Sections of Pharmacology. 2. The concept of medicinal substance, medicinal agent (medicinal drug, drug), medicinal form. 3. The concept of the pharmacological action and types of the action of drugs. 4. The sources of obtaining drugs. 5. International and national pharmacopeia, its content and purpose. 6. Pharmacy. Rules of drug storage and dispensing. 7. Prescription and its structure. Prescription forms. General rules for writing out a prescription. State regulation of writing out and dispensing drugs. 8. Name of medicinal products (international non-proprietary name - INN, trade name). 9. Peculiarities of writing out narcotic, poisonous and potent substances in prescription. 10. Drugs under control. Drugs prohibited for prescribing. 11. Solid medicinal forms: tablets, dragee (pills), powders, capsules. Their characteristics, advantages and disadvantages. Rules of prescribing. Write out prescriptions for: 1. 5 powders of Codeine 0.015 g. 1 powder orally twice a day. 2. 10 powders of Didanosine 0.25 g in sachets to prepare solution for internal use. Accept inside twice a day one sachet powder after dissolution in a glass of boiled water. 3. 50 mg of Alteplase powder in the bottle. Dissolve the content of the bottle in 50 ml of saline. First 15 ml introduce intravenously streamly, then intravenous drip.
    [Show full text]
  • Nomination Background: 1-Butyl-3-Methylimidazolium Chloride
    Ionic Liquids 1-Butyl-3-methylimidazolium Chloride (CAS No. 79917-90-1) 1-Butyl-1-methylpyrrolidinium Chloride (CAS No. 479500-35-1) N-Butylpyridinium Chloride (CAS No. 1124-64-7) Review of Toxicological Literature May 2004 Ionic Liquids 1-Butyl-3-methylimidazolium Chloride (CAS No. 79917-90-1) 1-Butyl-1-methylpyrrolidinium Chloride (CAS No. 479500-35-1) N-Butylpyridinium Chloride (CAS No. 1124-64-7) Review of Toxicological Literature Prepared for National Toxicology Program (NTP) National Institute of Environmental Health Sciences (NIEHS) National Institutes of Health U.S Department of Health and Human Services Contract No. N01-ES-35515 Project Officer: Scott A. Masten, Ph.D. NTP/NIEHS Research Triangle Park, North Carolina Prepared by Integrated Laboratory Systems, Inc. Research Triangle Park, North Carolina May 2004 Toxicological Summary for Ionic Liquids 05/2004 Abstract Ionic liquids are salts of organic cations with melting points generally below 100 °C and are being widely investigated as replacements for volatile organic solvents in industrial and laboratory processes because they are thought to be "environmentally benign." Although some efforts have begun to study their potential for ecotoxicity, limited vertebrate or genetic toxicity testing has been done. Three ionic liquids, 1-butyl-3-methylimidazolium chloride ([bmim]Cl), 1-butyl-1-methylpyrrolidinium chloride ([bmpy]Cl), and N-butylpyridinium chloride ([NBuPy]Cl), were nominated to the National Toxicology Program (NTP) for toxicological testing based on their widespread interest as possible alternatives to organic solvents. These chlorides are representative of the three most common cation classes of ionic liquids being investigated: imidazolium, pyridinium, and pyrrolidinium. The chlorides, soluble in water and polar organic liquids, are generally prepared from approximately equimolar amounts of the appropriately substituted heterocyclic compound and butyl chloride, often under both heat and pressure.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,716.252 B2 Schafer Et Al
    US008716252B2 (12) United States Patent (10) Patent No.: US 8,716.252 B2 Schafer et al. (45) Date of Patent: May 6, 2014 (54) (METHYLSULFONYL) ETHYL BENZENE (51) Int. Cl. ISONDOLINEDERVATIVES AND THEIR A613 L/70 (2006.01) PHARMACEUTICALUSES A613 L/40 (2006.01) C07H 17/02 (2006.01) (75) Inventors: Peter H. Schafer, Somerset, NJ (US); C07D 209/16 (2006.01) Anthony J. Frank, Easton, PA (US); (52) U.S. Cl. Hon-Wah Man, Princeton, NJ (US); Sai USPC ............. 514/27: 514/416:536/17.4: 548/472 L. Shankar, Chesterfield, NJ (US) (58) Field of Classification Search None (73) Assignee: Celgene Corporation, Summit, NJ (US) See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 0 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 13/518,843 6,667,316 B1* 12/2003 Man et al. ..................... 514,323 (22) PCT Filed: Dec. 21, 2010 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O10/06142O WO WOO1,34606 5, 2001 S371 (c)(1), * cited by examiner (2), (4) Date: Aug. 21, 2012 Primary Examiner — Traviss C McIntosh, III (87) PCT Pub. No.: WO2011/079091 (74) Attorney, Agent, or Firm — Jones Day PCT Pub. Date: Jun. 30, 2011 (57) ABSTRACT (65) Prior Publication Data Provided are (methylsulfonyl)ethyl benzene isoindoline US 2013/O1162O4 A1 May 9, 2013 compounds, and pharmaceutically acceptable salts, Solvates, O O or stereoisomers thereof. Methods of use and pharmaceutical Related U.S. Application Data compositions of these compounds are also disclosed.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0046244 A1 Rogers Et Al
    US 20120046244A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0046244 A1 Rogers et al. (43) Pub. Date: Feb. 23, 2012 (54) DUAL FUNCTIONING IONIC LIQUIDS AND (86). PCT No.: PCT/USO9/69652 SALTS THEREOF S371 (c)(1), (75) Inventors: Robin D. Rogers, Tuscaloosa, AL (2), (4) Date: Nov. 3, 2011 (US); Daniel T. Daly, Tuscaloosa, AL (US); Douglas MacFarlane, Related U.S. Application Data SG (KSR,kiSt. Port (60) Eyal application No. 61/141,168, filed on Dec. Seddon, Donaghadee (IE): s Gabriela Gurau, Tuscaloosa, AL O O (US); Katharina Bica, Vienna Publication Classification (AT); Jelena Turanjanin, Victoria (51) Int. Cl. (AU); Pamela M. Dean, Victoria A6II 3/66 (2006.01) (AU) A6II 3L/205 (2006.01) A6II 3/545 (2006.01) (73) Assignees: THE BOARD OF TRUSTEES OF A613/606 (2006.01) THE UNIVERSITY OF (52) U.S. Cl. ......... 514/75; 514/166; 514/555; 514/226.2 ALABAMA, Tuscaloosa, AL (US); QUEENS UNIVERSITY (57) ABSTRACT BELFAST, Belfast (UK); MONASH UNIVERSITY, Disclosed herein are ionic liquid compositions comprising Melbourne (AU) active pharmaceutical, biological, and nutritional com pounds, and methods of use. Further disclosed are composi (21) Appl. No.: 13/142.559 tions of matter including liquid ion pairs alone or in Solution and their use; compositions of ionic liquids that are solvated. (22) PCT Filed: Dec. 29, 2009 for example, hydrated and their uses. Patent Application Publication Feb. 23, 2012 Sheet 1 of 7 US 2012/0046244 A1 O 20 40 SO 8) O) Wit% Choline DPP Fig. 1 Patent Application Publication Feb. 23, 2012 Sheet 2 of 7 US 2012/0046244 A1 CN- P(Busal H, Vam 4.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Examination Questions Chapter I
    EXAMINATION QUESTIONS CHAPTER I. GENERAL PHARMACOLOGY AND PRESCRIPTION 1. Essence of pharmacology as a science. Parts and fields of modern pharmacology. 2. The chemical nature of the drug. Factors providing the therapeutic effect of drugs - the pharmacological effect and placebo effect. 3. Sources of drugs. Definition: medicinal agent (medicinal drug, drug), medicinal substance, medicinal form. 4. Stages of development of new medicines and therapeutic dental appointment toothpastes. 5. Types of pharmacotherapy. Deontological problems of pharmacotherapy. 6. Routes of drug administration into the body and their characteristic. 7. Pathological changes in the mucosa of mouth and dental tissues as a result use of medicines. 8. Absorption and distribution of drugs in the body. Bioavailability. Volume of distribution. 9. Transformation of drugs in the body. 10. Routes of elimination of drugs and their characteristics. Clearance. Semi-elimination period. 11. Excretion of drugs through the oral mucosa, the possible consequences. 12. Mechanisms of drug interactions with the receptors. The concept of receptors in pharmacology. 13. Pharmacodynamic drug interactions. Antagonism, synergism, their types. Character of change of drug effect (activity, efficacy), depending on the type of antagonism. 14. Types of action of drugs. 15. Dependence of action of drugs on the chemical structure and physico-chemical properties. 16. The concept of dose. Types doses. Principles and units of drug dosage. 17. The dependence of the action of drugs on the dose, age, gender, individual characteristics of the organism. Idiosyncrasy. 18. Change of action of drugs in their re-introduction. Addictive. Tachyphylaxis. Cumulation. Medicinal dependence. 19. Medical and social aspects of the drug addiction control.
    [Show full text]
  • Heteroaryl Compounds, Compositions Thereof, And
    (19) TZZ ZZ_T (11) EP 2 090 577 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 471/04 (2006.01) C07D 487/04 (2006.01) 05.04.2017 Bulletin 2017/14 C07D 498/04 (2006.01) A61K 31/4985 (2006.01) A61P 35/00 (2006.01) (21) Application number: 09006829.7 (22) Date of filing: 18.10.2007 (54) Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors Heteroarylverbindungen, diese enthaltende Zusammensetzungen und deren Verwendung als Proteinkinaseinhibitoren Composés héteroaryliques, compositions les contenant et leur utilisation en tant qu’inhibiteurs de protein kinases (84) Designated Contracting States: • Harris, Roy Leonard lll AT BE BG CH CY CZ DE DK EE ES FI FR GB GR San Diego HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE CA 92109 (US) SI SK TR • Shevlin, Graziella Isabel Designated Extension States: San Diego AL BA HR MK RS CA 92129 (US) • Huang, Dehua (30) Priority: 19.10.2006 US 853166 P San Diego CA 92130 (US) (43) Date of publication of application: • Schwarz, Kimberley Lyn 19.08.2009 Bulletin 2009/34 San Diego CA 92117 (US) (62) Document number(s) of the earlier application(s) in • Packard, Garrick K. accordance with Art. 76 EPC: San Diego 07861467.4 / 2 078 016 CA 92121 (US) • Parnes, Jason Simon (73) Proprietor: Signal Pharmaceuticals, LLC San Diego San Diego, CA 92121 (US) CA 92130 (US) • Papa, Patrick William (72) Inventors: Carlsbad • Mortensen, Deborah Sue CA 92008 (US) San Diego • Tehrani, Lida Radnia CA 92117 (US) San Diego • Mederos, Maria Mercedes Delgado CA 92131 (US) San Diego • Perrin-Ninkovic, Sophie CA 92126 (US) Carlsbad • Sapienza, John Joseph CA 92010 (US) Chula Vista • Riggs, Jennifer R.
    [Show full text]